Periscope Capital’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Periscope Capital’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$6.39K	–	943
2022 Q4	$6.39K	Hold	100,000	–	–	﹤0.01%	806
2022 Q3	$6K	Buy	+100,000	New	+$5.81K	﹤0.01%	1063
2022 Q2	–	Sell	-165,200	Closed	-$40K	–	1268
2022 Q1	$40K	Sell	165,200 -4,800	-3%	-$1.53K	﹤0.01%	1009
2021 Q4	$112K	Sell	170,000 -78,300	-32%	-$54.3K	﹤0.01%	811
2021 Q3	$164K	Hold	248,300	–	–	﹤0.01%	670
2021 Q2	$213K	Buy	+248,300	New	+$173K	0.01%	596

Periscope Capital's BIOTW Position: Q1 2023 in Review

Periscope Capital sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 100,000 shares — an estimated $6.39K sold.

Periscope Capital first reported a position in BIOTW in Q2 2021 and held it in 6 quarters. The position peaked at $213K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Periscope Capital reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Periscope Capital sold 100,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $6.39K.
Periscope Capital first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 6 quarters.
Periscope Capital's Biotech Acquisition Company Warrant position peaked at $213K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.